Diagnostic arthroscopy versus arthrocentesis as initial treatment for arthralgia of the temporomandibular joint

MCG0 个研究点目标入组 140 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•Patients aged > 18 years
•- Arthralgia of the TMJ, proven with a diagnostic intra-articular injection with Ultracain DS Forte (articaine 4% + 1:100.000 adrenalin; Aventis Pharma, Hoevelaken, The Netherlands).
•- TMJ pain still present after two weeks of NSAIDs (i.e. diclofenac 3 times daily 50mg)
•- Symptoms presenting unilaterally or bilaterally with a maximal Visual Analog Scale (VAS)-score < 30 mm during movement or function of the contralateral joint, after anesthetizing the to be treated joint (thus avoiding the contralateral joint to be the cause of a limited mouth opening).

•- Systemic rheumatic disease (such as rheumatoid arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus, Sjögren syndromes, psoriatic arthritis)
•- Connective tissue disease (such as Marfan syndrome, Ehlers-Danlos syndrome, Osteogenesis Imperfecta)
•- Bony ankylosis of the TMJ
•- Congenital or acquired dentofacial deformity
•- History of jaw trauma that resulted in jaw or joint pain, bony changes or mandibular growth restriction
•- Prior arthrocentesis, (diagnostic) arthroscopy or open-TMJ surgery
•- Psychiatric disorder (as diagnosed by a physician)
•- Unwillingness to receive one of the study treatments
•- Pregnancy at time of treatment
•- Concurrent use of steroids, sedatives, muscle relaxants or anti-inflammatory drugs other than the previously prescribed NSAIDs
•- Incompetence to speak the Dutch or English language
•- Medical comorbidities such as coagulation disorders, diabetes mellitus type I or II, kidney failure, heart failure, cardiac ischemia, hypertension and history of HIV.

发起方

MCG